Presentation is loading. Please wait.

Presentation is loading. Please wait.

Drug Interaction Between Complementary Herbal Medicines and Gefitinib

Published byLuboš Lukáš Prokop Modified over 5 years ago

Similar presentations

Presentation on theme: "Drug Interaction Between Complementary Herbal Medicines and Gefitinib"— Presentation transcript:

1 Drug Interaction Between Complementary Herbal Medicines and Gefitinib
Sung-Wook Hwang, MD, Hye-Suk Han, MD, Kun Young Lim, MD, Ji-Youn Han, MD, PhD  Journal of Thoracic Oncology  Volume 3, Issue 8, Pages (August 2008) DOI: /JTO.0b013e f1e Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Chest CT before and after gefitinib treatment. Initial CT scan at the level of right lower lobar bronchus revealed a speculated mass with cavitary change in the right lower lobe suggesting primary lung cancer. Multiple hematogenous metastatic nodules with or without cavitary change were seen in both lungs (A). On CT scan obtained 9 weeks after gefitinib treatment, the primary mass in the right lower lobe and pulmonary metastases in both lungs were increased (B). On CT scan obtained 4 weeks after discontinuation of herbal medicines, primary mass and hematogenous metastatic nodules were markedly decreased (C). On CT scan obtained a total of 30 weeks after gefitinib treatment, the primary mass in the right lower lobe was further decreased (D). Journal of Thoracic Oncology 2008 3, DOI: ( /JTO.0b013e f1e) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Drug Interaction Between Complementary Herbal Medicines and Gefitinib"

Similar presentations

The Accuracy of Frozen Section Diagnosis of Pulmonary Nodules: Evaluation of Inflation Method during Intraoperative Pathology Consultation with Cryosection.

The Accuracy of Frozen Section Diagnosis of Pulmonary Nodules: Evaluation of Inflation Method during Intraoperative Pathology Consultation with Cryosection.
Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer  Haa-Na Song, MD,

Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer  Haa-Na Song, MD,
Kazuma Nagata, MD, Reiko Kaji, MD, Keisuke Tomii, MD 

Kazuma Nagata, MD, Reiko Kaji, MD, Keisuke Tomii, MD 
Sukki Cho, MD, Kyung-Min Ryu, MD, Yoon-Jin Hwang, MD, Eung Bae Lee, MD 

Sukki Cho, MD, Kyung-Min Ryu, MD, Yoon-Jin Hwang, MD, Eung Bae Lee, MD 
Volume 30, Issue 2, Pages (August 1956)

Volume 30, Issue 2, Pages (August 1956)
Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.
Lung Cancer with Unusual Presentation as a Thin-Walled Cyst in a Young Nonsmoker  Chou-Chin Lan, MD, Hong-Cheng Wu, MD, Chih-Hsin Lee, MD, Shiu-Feng Huang,

Lung Cancer with Unusual Presentation as a Thin-Walled Cyst in a Young Nonsmoker  Chou-Chin Lan, MD, Hong-Cheng Wu, MD, Chih-Hsin Lee, MD, Shiu-Feng Huang,
Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease  Eisaku.

Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease  Eisaku.
Hironori Yoshida, MD, Young Hak Kim, MD  Journal of Thoracic Oncology 

Hironori Yoshida, MD, Young Hak Kim, MD  Journal of Thoracic Oncology 
Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment  Jun Soo Ham, MD, Seokhwi Kim, MD, Hee Kyung.

Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment  Jun Soo Ham, MD, Seokhwi Kim, MD, Hee Kyung.
Abscopal Effect of Nivolumab in a Patient with Primary Lung Cancer

Abscopal Effect of Nivolumab in a Patient with Primary Lung Cancer
Leptomeningeal and Medullary Response to Second-Line Erlotinib in Lung Adenocarcinoma  Mathilde Wagner, MD, Benjamin Besse, MD, Corinne Balleyguier, MD,

Leptomeningeal and Medullary Response to Second-Line Erlotinib in Lung Adenocarcinoma  Mathilde Wagner, MD, Benjamin Besse, MD, Corinne Balleyguier, MD,
Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer  Haa-Na Song, MD,

Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer  Haa-Na Song, MD,
David T. Cooke, MD, Dennis J. Zheng, Karen A. Peterson, NP, Royce F

David T. Cooke, MD, Dennis J. Zheng, Karen A. Peterson, NP, Royce F
OPG/RANKL/RANK Pathway as a Therapeutic Target in Cancer

OPG/RANKL/RANK Pathway as a Therapeutic Target in Cancer
Joachim Pfannschmidt, MD, Hans Hoffmann, MD, Hendrick Dienemann, MD 

Joachim Pfannschmidt, MD, Hans Hoffmann, MD, Hendrick Dienemann, MD 
First-Line Gefitinib Treatment for Patients with Advanced Non-small Cell Lung Cancer with Poor Performance Status  Young Joo Lee, MD, Heung Tae Kim, MD,

First-Line Gefitinib Treatment for Patients with Advanced Non-small Cell Lung Cancer with Poor Performance Status  Young Joo Lee, MD, Heung Tae Kim, MD,
A Novel Strategy for Treatment of Metastatic Pulmonary Tumors: Radiofrequency Ablation in Conjunction with Surgery  Yoshifumi Sano, MD, Susumu Kanazawa,

A Novel Strategy for Treatment of Metastatic Pulmonary Tumors: Radiofrequency Ablation in Conjunction with Surgery  Yoshifumi Sano, MD, Susumu Kanazawa,
Electronic Updates for JTO Readers

Electronic Updates for JTO Readers
Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement– Positive Non–Small-Cell Lung Cancer  Hiroyasu Kaneda, MD, PhD, Isamu.

Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement– Positive Non–Small-Cell Lung Cancer  Hiroyasu Kaneda, MD, PhD, Isamu.

Similar presentations

Ads by Google